Christianne J. M. de Groot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christianne J. M. de Groot has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Ben Willem Mol
Department of Obstetrics and Gynaecology Monash University Clayton Victoria Australia
5 shared publications - Kitty W. M. Bloemenkamp
Department of Obstetrics, Wilhelmina Children's Hospital, University Medical Center Utrecht , Utrecht
5 shared publications - Jouke T. Tamsma
Section of Vascular Medicine, Department of Endocrinology and Internal Medicine, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
4 shared publications - Maria Gabriel Van Pampus
OLVG Department Obstetrics and Gynecology
4 shared publications - Martina Porath
Department of Obstetrics and Gynecology, Máxima Medical Centre, Veldhoven, the Netherlands
4 shared publications - Arie Franx
Department of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, The Netherlands
2 shared publications
Latest Publications
- 18 September 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (9) , e227667
Recovery of second trimester pre-eclampsia after fetal reduction of a triplet
Women with a multiple pregnancy are at increased risk of developing hypertensive disorders of pregnancy. We describe a case of a dichorionic triamniotic triplet pregnancy complicated by severe hypertension, proteinuria and maternal symptoms, fitting with the diagnosis of pre-eclampsia, apart from the early gestational age of only 16 weeks. After reduction of the monochorionic pair, the disease resolved and pre-eclampsia was diagnosed again at 30 weeks of gestation, resulting in a delivery on maternal indication at 33 weeks of gestation. In a review of the literature, we found six papers including eight cases on multifetal pregnancy reduction on maternal indication. Multifetal pregnancy reduction resulted in a prolongation of pregnancy of two to 21 weeks and may be considered in extreme early onset pre-eclampsia in dichorionic multiple pregnancies.
- 18 September 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (9) , e227667
Recovery of second trimester pre-eclampsia after fetal reduction of a triplet
Women with a multiple pregnancy are at increased risk of developing hypertensive disorders of pregnancy. We describe a case of a dichorionic triamniotic triplet pregnancy complicated by severe hypertension, proteinuria and maternal symptoms, fitting with the diagnosis of pre-eclampsia, apart from the early gestational age of only 16 weeks. After reduction of the monochorionic pair, the disease resolved and pre-eclampsia was diagnosed again at 30 weeks of gestation, resulting in a delivery on maternal indication at 33 weeks of gestation. In a review of the literature, we found six papers including eight cases on multifetal pregnancy reduction on maternal indication. Multifetal pregnancy reduction resulted in a prolongation of pregnancy of two to 21 weeks and may be considered in extreme early onset pre-eclampsia in dichorionic multiple pregnancies.
- 1 September 2015
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 29 (6) , 481-489
A Longitudinal Analysis of Publications on Maternal Mortality
Background The fifth Millennium Development Goal formulated by the WHO in, aimed to reduce global maternal mortality by, in, . We studied the extent to which medical research has supported this by studying maternal mortality. We performed a bibliometric analysis of the literature on maternal mortality and of the development of this literature over time. Methods We searched for publications on maternal mortality in the Web of Science database in the period, . We visualised the subjects of these publications using a term map showing the most significant terms occurring in the titles and abstracts of publications on maternal mortality. Results We identified, publications on maternal mortality in Web of Science. The annual number increased from, in, to, in, . The largest number of maternal mortality publications was found in the field of Obstetrics and Gynecology, followed by the Public, Environmental, and Occupational Health field, increase from, until, of, and, respectively, . In both fields, the number of maternal mortality publications has increased at a much higher rate than the overall number of publications in the field. Conclusions In line with the focus of the fifth Millennium Development Goal on reducing maternal mortality, during the past, years, there has been a steady increase in the amount of attention paid to maternal mortality in the medical literature. This is largely driven by an increase, mainly in recent years, in public health research on maternal mortality.Christianne J. M. de Groot, Thed van Leeuwen, Ben Willem J. Mol, and Ludo Waltma
- 1 September 2015
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 29 (6) , 481-489
A Longitudinal Analysis of Publications on Maternal Mortality
Background The fifth Millennium Development Goal formulated by the WHO in, aimed to reduce global maternal mortality by, in, . We studied the extent to which medical research has supported this by studying maternal mortality. We performed a bibliometric analysis of the literature on maternal mortality and of the development of this literature over time. Methods We searched for publications on maternal mortality in the Web of Science database in the period, . We visualised the subjects of these publications using a term map showing the most significant terms occurring in the titles and abstracts of publications on maternal mortality. Results We identified, publications on maternal mortality in Web of Science. The annual number increased from, in, to, in, . The largest number of maternal mortality publications was found in the field of Obstetrics and Gynecology, followed by the Public, Environmental, and Occupational Health field, increase from, until, of, and, respectively, . In both fields, the number of maternal mortality publications has increased at a much higher rate than the overall number of publications in the field. Conclusions In line with the focus of the fifth Millennium Development Goal on reducing maternal mortality, during the past, years, there has been a steady increase in the amount of attention paid to maternal mortality in the medical literature. This is largely driven by an increase, mainly in recent years, in public health research on maternal mortality.Christianne J. M. de Groot, Thed van Leeuwen, Ben Willem J. Mol, and Ludo Waltma
- 12 December 2014
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 174 (6) , 819-825
Reproductive outcomes of women and men born very preterm and/or with a very low birth weight in 1983: a longitudinal cohort study in the Netherlands
The aims of this study were to analyze reproductive outcomes of women and men born very preterm (gestational age Conclusion: This study indicates that women and men born VP or with a VLBW have reduced reproductive rates at the age of 28 compared to the total Dutch population at a similar age.
- 12 December 2014
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 174 (6) , 819-825
Reproductive outcomes of women and men born very preterm and/or with a very low birth weight in 1983: a longitudinal cohort study in the Netherlands
The aims of this study were to analyze reproductive outcomes of women and men born very preterm (gestational age Conclusion: This study indicates that women and men born VP or with a VLBW have reduced reproductive rates at the age of 28 compared to the total Dutch population at a similar age.
- 1 October 2014
- Published by Elsevier in Pregnancy Hypertension
- Vol. 4 (4) , 264-270
Cost-effectiveness analysis of cardiovascular risk factor screening in women who experienced hypertensive pregnancy disorders at term
- 1 October 2014
- Published by Elsevier in Pregnancy Hypertension
- Vol. 4 (4) , 264-270
Cost-effectiveness analysis of cardiovascular risk factor screening in women who experienced hypertensive pregnancy disorders at term
- Open Access
- 4 June 2013
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 13 (1) , 126
Cardiovascular risk estimation in women with a history of hypertensive pregnancy disorders at term: a longitudinal follow-up study
Cardiovascular disease is associated with major morbidity and mortality in women in the Western world. Prediction of an individual cardiovascular disease risk in young women is difficult. It is known that women with hypertensive pregnancy complications have an increased risk for developing cardiovascular disease in later life and pregnancy might be used as a cardiovascular stress test to identify women who are at high risk for cardiovascular disease. In this study we assess the possibility of long term cardiovascular risk prediction in women with a history of hypertensive pregnancy disorders at term. In a longitudinal follow-up study, between June 2008 and November 2010, 300 women with a history of hypertensive pregnancy disorders at term (HTP cohort) and 94 women with a history of normotensive pregnancies at term (NTP cohort) were included. From the cardiovascular risk status that was known two years after index pregnancy we calculated individual (extrapolated) 10-and 30-year cardiovascular event risks using four different risk prediction models including the Framingham risk score, the SCORE score and the Reynolds risk score. Continuous data were analyzed using the Student’s T test and Mann–Whitney U test and categorical data by the Chi-squared test. A poisson regression analysis was performed to calculate the incidence risk ratios and corresponding 95% confidence intervals for the different cardiovascular risk estimation categories. After a mean follow-up of 2.5 years, HTP women had significantly higher mean (SD) extrapolated 10-year cardiovascular event risks (HTP 7.2% (3.7); NTP 4.4% (1.9) (p<.001, IRR 5.8, 95% CI 1.9 to 19)) and 30-year cardiovascular event risks (HTP 11% (7.6); NTP 7.3% (3.5) (p<.001, IRR 2.7, 95% CI 1.6 to 4.5)) as compared to NTP women calculated by the Framingham risk scores. The SCORE score and the Reynolds risk score showed similar significant results. Women with a history of gestational hypertension or preeclampsia at term have higher predicted (extrapolated) 10-year and 30-year cardiovascular event risks as compared to women with a history of uncomplicated pregnancies. Further large prospective studies have to evaluate whether hypertensive pregnancy disorders have to be included as an independent variable in cardiovascular risk prediction models for women.
- 4 June 2013
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 13 (1) , 126
Open AccessCardiovascular risk estimation in women with a history of hypertensive pregnancy disorders at term: a longitudinal follow-up study
Cardiovascular disease is associated with major morbidity and mortality in women in the Western world. Prediction of an individual cardiovascular disease risk in young women is difficult. It is known that women with hypertensive pregnancy complications have an increased risk for developing cardiovascular disease in later life and pregnancy might be used as a cardiovascular stress test to identify women who are at high risk for cardiovascular disease. In this study we assess the possibility of long term cardiovascular risk prediction in women with a history of hypertensive pregnancy disorders at term. In a longitudinal follow-up study, between June 2008 and November 2010, 300 women with a history of hypertensive pregnancy disorders at term (HTP cohort) and 94 women with a history of normotensive pregnancies at term (NTP cohort) were included. From the cardiovascular risk status that was known two years after index pregnancy we calculated individual (extrapolated) 10-and 30-year cardiovascular event risks using four different risk prediction models including the Framingham risk score, the SCORE score and the Reynolds risk score. Continuous data were analyzed using the Student’s T test and Mann–Whitney U test and categorical data by the Chi-squared test. A poisson regression analysis was performed to calculate the incidence risk ratios and corresponding 95% confidence intervals for the different cardiovascular risk estimation categories. After a mean follow-up of 2.5 years, HTP women had significantly higher mean (SD) extrapolated 10-year cardiovascular event risks (HTP 7.2% (3.7); NTP 4.4% (1.9) (p<.001, IRR 5.8, 95% CI 1.9 to 19)) and 30-year cardiovascular event risks (HTP 11% (7.6); NTP 7.3% (3.5) (p<.001, IRR 2.7, 95% CI 1.6 to 4.5)) as compared to NTP women calculated by the Framingham risk scores. The SCORE score and the Reynolds risk score showed similar significant results. Women with a history of gestational hypertension or preeclampsia at term have higher predicted (extrapolated) 10-year and 30-year cardiovascular event risks as compared to women with a history of uncomplicated pregnancies. Further large prospective studies have to evaluate whether hypertensive pregnancy disorders have to be included as an independent variable in cardiovascular risk prediction models for women.
- 1 July 2012
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 67 (7) , 389-391
Neonatal Morbidity After Induction Vs Expectant Monitoring in Intrauterine Growth Restriction at Term
The Disproportionate Intrauterine Growth Intervention Trial at Term (DIGITAT) was a randomized controlled trial that prospectively observed children with suspected intrauterine growth restriction (IUGR) at term. DIGITAT was designed to investigate whether induction of labor for pregnancies with suspected IUGR beyond 36 weeks of gestation reduced neonatal morbidity and mortality compared with an expectant approach with fetal and maternal surveillance. Data from that trial showed no significant differences between the 2 approaches in primary fetal outcomes (a composite of perinatal death, abnormal umbilical arterial cord pH and Apgar scores or admission to neonatal intensive care unit as well as comparable operative delivery rates. However, more children in the induction group than in the expectant group were admitted to an intermediate level of care (48% vs 36%). It was possible that this difference in admissions was due to complications of late prematurity because children in the induction group were born, on average, 10 days earlier than did those in the expectant group. It also seemed possible that the difference was not due to clinically relevant morbidity but was associated with policies for admission to intermediate levels of care related to prematurity. The present study performed secondary analysis of the DIGITAT data to resolve these 2 competing explanations. The net effect of the 2 policies on neonatal morbidity was studied in detail using the Morbidity Assessment Index for Newborns (MAIN) score, a validated outcome measure for neonatal morbidity. Babies born to mothers with suspected IUGR were randomized to either induction (n = 308) or expectant monitoring (n = 315). There were no differences between the induction and expectant group in mean MAIN scores or in MAIN morbidity categories. Neonatal admissions were lower in both groups after 38 weeks of pregnancy than before 38 weeks. This finding suggests that a policy of induction does not increase short-term neonatal morbidity. Moreover, the data show that, when induction for near-term growth restriction is considered because of possible stillbirth, it may be reasonable to delay delivery until 38 weeks.
- 1 July 2012
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 67 (7) , 389-391
Neonatal Morbidity After Induction Vs Expectant Monitoring in Intrauterine Growth Restriction at Term
The Disproportionate Intrauterine Growth Intervention Trial at Term (DIGITAT) was a randomized controlled trial that prospectively observed children with suspected intrauterine growth restriction (IUGR) at term. DIGITAT was designed to investigate whether induction of labor for pregnancies with suspected IUGR beyond 36 weeks of gestation reduced neonatal morbidity and mortality compared with an expectant approach with fetal and maternal surveillance. Data from that trial showed no significant differences between the 2 approaches in primary fetal outcomes (a composite of perinatal death, abnormal umbilical arterial cord pH and Apgar scores or admission to neonatal intensive care unit as well as comparable operative delivery rates. However, more children in the induction group than in the expectant group were admitted to an intermediate level of care (48% vs 36%). It was possible that this difference in admissions was due to complications of late prematurity because children in the induction group were born, on average, 10 days earlier than did those in the expectant group. It also seemed possible that the difference was not due to clinically relevant morbidity but was associated with policies for admission to intermediate levels of care related to prematurity. The present study performed secondary analysis of the DIGITAT data to resolve these 2 competing explanations. The net effect of the 2 policies on neonatal morbidity was studied in detail using the Morbidity Assessment Index for Newborns (MAIN) score, a validated outcome measure for neonatal morbidity. Babies born to mothers with suspected IUGR were randomized to either induction (n = 308) or expectant monitoring (n = 315). There were no differences between the induction and expectant group in mean MAIN scores or in MAIN morbidity categories. Neonatal admissions were lower in both groups after 38 weeks of pregnancy than before 38 weeks. This finding suggests that a policy of induction does not increase short-term neonatal morbidity. Moreover, the data show that, when induction for near-term growth restriction is considered because of possible stillbirth, it may be reasonable to delay delivery until 38 weeks.
- 1 May 2012
- Published by Elsevier in The Journal of Pediatrics
- Vol. 160 (5) , 844-848.e1
E-Selectin is Elevated in Cord Blood of South Asian Neonates Compared with Caucasian Neonates
- 1 May 2012
- Published by Elsevier in The Journal of Pediatrics
- Vol. 160 (5) , 844-848.e1
E-Selectin is Elevated in Cord Blood of South Asian Neonates Compared with Caucasian Neonates
- Open Access
- 7 July 2011
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 11 (1) , 50
Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks' gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial
Gestational hypertension (GH) and pre-eclampsia (PE) can result in severe complications such as eclampsia, placental abruption, syndrome of Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP) and ultimately even neonatal or maternal death. We recently showed that in women with GH or mild PE at term induction of labour reduces both high risk situations for mothers as well as the caesarean section rate. In view of this knowledge, one can raise the question whether women with severe hypertension, pre-eclampsia or deterioration chronic hypertension between 34 and 37 weeks of gestation should be delivered or monitored expectantly. Induction of labour might prevent maternal complications. However, induction of labour in late pre-term pregnancy might increase neonatal morbidity and mortality compared with delivery at term.
- 7 July 2011
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 11 (1) , 50
Open AccessInduction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia between 34 and 37 weeks' gestation (HYPITAT-II): a multicentre, open-label randomised controlled trial
Gestational hypertension (GH) and pre-eclampsia (PE) can result in severe complications such as eclampsia, placental abruption, syndrome of Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP) and ultimately even neonatal or maternal death. We recently showed that in women with GH or mild PE at term induction of labour reduces both high risk situations for mothers as well as the caesarean section rate. In view of this knowledge, one can raise the question whether women with severe hypertension, pre-eclampsia or deterioration chronic hypertension between 34 and 37 weeks of gestation should be delivered or monitored expectantly. Induction of labour might prevent maternal complications. However, induction of labour in late pre-term pregnancy might increase neonatal morbidity and mortality compared with delivery at term.
- Open Access
- 1 June 2011
- Published by MDPI AG in Clinics and Practice
- Vol. 1 (3) , e55
Primary Sclerosing Cholangitis and Pregnancy
Primary sclerosing cholangitis is a progressive disease, and coincidentally in pregnancy it is rare. It is characterized by progressive inflammation and destruction of bile ducts finally resulting in liver failure. A rare case of primary sclerosing cholangitis in pregnancy is presented. The course of the pregnancy was marked by threatened preterm delivery and exacerbation of cholestasis. She was successfully treated with ursodeoxycholic acid (UDCA). Although, primary sclerosing cholangitis has both maternal and fetal effects on pregnancy, the overall outcome is favorable. Only few cases have been reported using high dose ursodeoxycholic acid for primary sclerosing cholangitis in pregnancy, it often improves pruritus but has no protection against stillbirth. Data on the safety to the fetus or neonate and long-term outcome are scarce.
- 1 June 2011
- Published by MDPI AG in Clinics and Practice
- Vol. 1 (3) , e55
Open AccessPrimary Sclerosing Cholangitis and Pregnancy
Primary sclerosing cholangitis is a progressive disease, and coincidentally in pregnancy it is rare. It is characterized by progressive inflammation and destruction of bile ducts finally resulting in liver failure. A rare case of primary sclerosing cholangitis in pregnancy is presented. The course of the pregnancy was marked by threatened preterm delivery and exacerbation of cholestasis. She was successfully treated with ursodeoxycholic acid (UDCA). Although, primary sclerosing cholangitis has both maternal and fetal effects on pregnancy, the overall outcome is favorable. Only few cases have been reported using high dose ursodeoxycholic acid for primary sclerosing cholangitis in pregnancy, it often improves pruritus but has no protection against stillbirth. Data on the safety to the fetus or neonate and long-term outcome are scarce.
- 11 May 2011
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 5,p. CD008128
Treatment of valvular heart disease during pregnancy for improving maternal and neonatal outcome
Valvular heart disease constitutes the majority of all causes of heart disease in pregnancy. In the presence of valvular heart disease, the necessary haemodynamic changes of pregnancy might cause heart failure, leading to severe maternal and fetal morbidity and even mortality. Treatment of valvular heart disease is indicated when patients experience a deterioration of symptoms and in case of a severe valvular lesion. Whether medical therapy or interventional therapy is the optimal treatment for both mother and child is unclear. To assess effectiveness and adverse effects of the different treatment modalities of valvular heart disease in pregnancy to improve maternal and neonatal outcomes. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 March 2011), EMBASE (1980 to 23 March 2011) and the reference lists of background review articles. Randomised controlled trials, quasi-randomised controlled and cluster-randomised controlled trials comparing medical therapy with percutaneous or surgical intervention for the treatment of valvular heart disease in pregnancy. We identified no (randomised) controlled trials to assess the effectiveness and adverse effects of the treatment of valvular heart disease in pregnancy. There were no randomised controlled trials, quasi-randomised controlled trials or cluster-randomised trials identified from the search strategy. There is insufficient evidence to define the most effective treatment of valvular heart disease in pregnancy to improve maternal and neonatal outcomes.
- 11 May 2011
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 5,p. CD008128
Treatment of valvular heart disease during pregnancy for improving maternal and neonatal outcome
Valvular heart disease constitutes the majority of all causes of heart disease in pregnancy. In the presence of valvular heart disease, the necessary haemodynamic changes of pregnancy might cause heart failure, leading to severe maternal and fetal morbidity and even mortality. Treatment of valvular heart disease is indicated when patients experience a deterioration of symptoms and in case of a severe valvular lesion. Whether medical therapy or interventional therapy is the optimal treatment for both mother and child is unclear. To assess effectiveness and adverse effects of the different treatment modalities of valvular heart disease in pregnancy to improve maternal and neonatal outcomes. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 March 2011), EMBASE (1980 to 23 March 2011) and the reference lists of background review articles. Randomised controlled trials, quasi-randomised controlled and cluster-randomised controlled trials comparing medical therapy with percutaneous or surgical intervention for the treatment of valvular heart disease in pregnancy. We identified no (randomised) controlled trials to assess the effectiveness and adverse effects of the treatment of valvular heart disease in pregnancy. There were no randomised controlled trials, quasi-randomised controlled trials or cluster-randomised trials identified from the search strategy. There is insufficient evidence to define the most effective treatment of valvular heart disease in pregnancy to improve maternal and neonatal outcomes.